ScholarLens Back to search
2001•Digital Access to Scholarship at Harvard (DASH) (Harvard University)Open access

Ephedra and the FDA

Brandi E. Ehlers

Open full text 0 citations

Abstract

(Article begins on next page) The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters. Citation Ephedra and the FDA (2001 Third Year Paper)

Open-access reader

About this research paper

What this paper is about

(Article begins on next page) The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters. Citation Ephedra and the FDA (2001 Third Year Paper)

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

(Article begins on next page) The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters. Citation Ephedra and the FDA (2001 Third Year Paper)

Key concepts: Safeguarding, Agency (philosophy), Business, Drug approval, Intervention (counseling), Public health, Approved drug, Medicine

Related papers

Related paper 1Related paper 2Related paper 3
Back to paper searchBrowse research topicsOriginal source
Ephedra and the FDA — Research Paper | ScholarLens